470 Results
Sort By:
Published on July 12, 2023
A new study from researchers at the Mass General Cancer Center has uncovered a protein that is implicated in lung cancer resistance to tyrosine kinase inhibitor (TKI) therapies. The research, published Wednesday in Nature suggest the protein, APOBEC3A, could be a promising target for therapeutic development. “Traditionally, we treat patients…
Published on June 22, 2022
Researchers at Moffitt Cancer Center report they have discovered a mechanism by which prostate cancer cells become resistant through molecular modification of the androgen receptor protein and identified a potential treatment approach that could overcome this resistance in mice. Their findings are published in the journal Science Translational Medicine in a paper…
Published on March 22, 2021
A new study suggests neutrophil metabolism determines how these immune cells support lung cancer tumors, making them more drug resistant. The researchers say this could point to a “Achille’s heel,” for lung tumors, allowing for novel treatment approaches. The team was led by Etienne Meylan at EPFL’s School of Life…
Published on March 20, 2024
A study led by the Science and Technology Facilities Council (STFC) Central Laser Facility (CLF) has demonstrated for the first time that a crucial interface in a protein that drives EGFR resistance to targeted cancer therapies could act as a target for more effective treatments. This research, published in Nature…
Published on November 1, 2023
New research reveals that an important priming phase makes breast cancer cells previously exposed to sublethal drug concentrations refractory to higher doses. Using spatiotemporal modeling, a University of Ottawa (uOttawa) team found, specifically, that chemotherapy-resistant breast cancer cells throughout the cellular concentration gradient have higher expression of the solute carriers…
Published on October 25, 2023
New research points to lactate-producing intratumoral bacteria as a driving cause of radiation therapy resistance in cervical cancer. The study, published in Cancer Cell, found that Lactobacillus iners (L. iners), causes cervical cancer cells to respond to radiation by rewiring metabolic signaling pathways that ultimately lead to radiation resistance. The researchers also…
Published on September 27, 2023
A new compound called d16 that reduces tumor growth and overcomes treatment resistance in mutant p53-bearing cancers has been developed by researchers at the Baylor College of Medicine. Their findings testing the compound, published in the journal Cancer Research Communications, suggests the new compound could be used in combination therapies…
Published on June 21, 2023
It’s long been known that cancer patients have excess sugar in their urine, now new research affirms that insulin resistance, a distinctive feature in diabetics, is common in cancer patients. Since insulin resistance can lead to tumor growth, this finding suggests further research on whether treating this condition for people…
Published on April 11, 2023
Research led by the University of Basel shows that the antioxidant and dietary supplement N-acetylcysteine could help combat a type of drug resistance in breast cancer. The PI3K signaling pathway is commonly overactive in breast cancer patients due to genetic mutations. The approval of the PI3K inhibitor alpelisib by the…
Published on March 22, 2023
A new study, led by investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has demonstrated for the first time the method by which immature neutrophils, a type of white blood cell are controlled by pancreatic cancers to drive both immunosuppression and treatment resistance.…
Published on March 8, 2023
Researchers have discovered a mechanism by which chemoresistant ovarian cancer cells signal neighboring cells to fall into a similar resistant state. A team from the University of Pittsburgh observed that so-called quiescent ovarian cancer cells, which are characterized by very slow growth, overexpress a normal ovarian protein called follistatin. That…
Published on October 19, 2022
About one-quarter of of recurrent estrogen receptor–positive (ER+) breast cancers lose ER expression making them resistant to endocrine therapy say researchers from Baylor College of Medicine in new research published in the Proceedings of the National Academy of Sciences. Two cellular proteins known as 14-3-3τ and ERα36 have been previously…
Published on October 17, 2022
Researchers at the Hospital del Mar medical research institute (IMIM) in Barcelona, Spain have discovered how to overcome a treatment resistance mechanism in one of the most aggressive types of breast cancer by activating the body’s immune response. HER2 positive breast cancer tends to grow faster, spread and recur more…
Published on August 24, 2022
According to the CDC, the general five-year survival rate for people with pancreatic cancer in the United States is 11%. Better treatments and understanding of the disease are needed. A new study in mice, published in Nature Genetics, by researchers at Washington University School of Medicine in St. Louis reveals…
Published on August 18, 2022
Scientists at the University of Michigan have developed an anti-cancer drug that is absorbed through the gut’s lymphatic system potentially outmaneuvering the molecular signaling pathways that lead to drug resistance, while increasing cancer-fighting ability and reducing side effects. Their findings demonstrate that the kinase inhibitor significantly reduced disease, limited toxicity,…